AI Article Synopsis

  • Eosinophilic pustular folliculitis (EPF) is a rare inflammatory skin disease mainly involving eosinophils and can appear in both follicle areas and less commonly in follicle-free areas.
  • This case study details two patients with difficult-to-treat EPF who had previous treatment failures with various standard therapies.
  • Both patients responded positively to the medication abrocitinib, achieving complete remission in one week and four weeks, with no side effects reported, suggesting it could be a safe treatment option for EPF.

Article Abstract

Eosinophilic pustular folliculitis (EPF) is a rare, non-infectious, inflammatory disease characterized by an eosinophil-dominated infiltrate within and around pilosebaceous units. Sometimes, EPF manifests with eruptions in follicle-free areas, although it is not common, and treatment may be difficult. In this case study we report two patients with refractory EPF who presented with eruptions of both classic follicle areas and follicle-free areas. These two patients were successfully treated with abrocitinib after treatment failure with several traditional therapies, such as indomethacin, steroids, and cyclosporin. One patient achieved complete remission at week 4 and the other at week 1, with no reported adverse effects. Therefore, we believe that abrocitinib may be a viable and safe therapeutic option for refractory EPF.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.17284DOI Listing

Publication Analysis

Top Keywords

eosinophilic pustular
8
pustular folliculitis
8
treated abrocitinib
8
follicle-free areas
8
refractory epf
8
cases eosinophilic
4
folliculitis treated
4
abrocitinib eosinophilic
4
epf
4
folliculitis epf
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!